Sewanti Limaye's research while affiliated with Sir H. N. Hospital and Research Centre and other places

... This persists despite breakthroughs in therapeutic options, including surgery, resection, chemotherapy and radiotherapy used individually or in combination [3]. Additionally, 10-20% of patients with early-stage CC and up to 70% of those with locally advanced CC experience cancer reoccurrence following surgery or radiation therapy [4]. This cancer recurrence may stem from tumor cells losing their sensitivity to chemotherapy and radiation treatment, ultimately contributing to unfavorable prognoses and heightened recurrence risks. ...

... The latter surgical approach removes the interface zone in its entirety. We believe this observation is related to the emerging understanding that breast cancer is a systemic disease, even in its early stages, as supported by the detection of circulating tumor cells [3]. These cells, when reactivated, can infiltrate the index breast quadrant and cause local recurrence near the interface zone. ...

... The oral medicine in question has been produced by Pfizer and is employed for the therapeutic management of specific forms of cancer, including HER2-negative advanced breast cancer characterized by distinct genetic alterations. Talzenna (Talazoparib) functions in a manner akin to other inhibitors of PARP-1, effectively impeding the enzymatic activity of PARP enzymes, specifically PARP-1, which play a crucial role in the process of DNA repair [43]. The suppression of PARP in cancer cells harboring certain genetic abnormalities, such as BRCA1 or BRCA2 mutations, or other impairments in DNA repair pathways, results in the accumulation of DNA damage and subsequent cell death [44]. ...

... However, parental VQ-D2 cells show little to no expression of FGFR1-4 at the mRNA level, comparable to control plasma cells ( Figure S6A) and do not harbor any mutations in FGFR1-4 either (our unpublished results). To determine if FGFR inhibition plays a role in Pon efficacy, we next tested the FGFR1 inhibitor sorafenib 17 , the FGFR1-3 inhibitor pazopanib 18 , and the pan-FGFR inhibitors dovitinib and lenvatinib 19,20 in our VQ MM cell lines. Similar as other TKIs tested in the AOD IX panel, none of the FGFR inhibitors displayed single agent efficacy at 100 nM and 1000 nM or in combination with Tra ( Figure S6B), suggesting that the efficacy of Pon in VQ MM cells is not primarily mediated through FGFR signaling. ...

... Inhibitors targeting PDGFR, VEGFR, or FGFR family receptors and Ret: Tumor angiogenesis is a hallmark of cancer. Several growth factors and their receptors, such as platelet-derived growth factor (PDGF)/PDGFR, vascular endothelial growth factor (VEGF)/VEGFR, fibroblast growth factor (FGF)/FGFR, stem cell factor (SCF)/c-Kit, glial cell line-derived neurotrophic factor (GDNF)-family ligands/ rearranged during transfection (RET), and angiopoietin/Tie 22,111 , regulate the growth, differentiation and migration of cancer cells and angiogenic activities of vascular endothelial cells 22,111 . PDGFs are members of the 'cysteine knot' growth factor superfamily, the members of which contain at least three disulfide bridges and forms homo-or heterodimers 112 . ...

... They have followed a step-by-step process (modified Delphi) that is both transparent and fair. 2 Most authors focus on numbers. In the development of guidelines, they sometimes forget that the document will finally be used by the community oncologists who otherwise may not have access to the expertise and mentorship of a senior experienced colleague. ...

... 2 Obtaining an adequate tumor sample can be clinically challenging due to an inaccessible tumor location or late presentation with metastatic disease at diagnosis. 2 The quality of one-third of core biopsy specimens was not found to be appropriate for novel immune biomarker discovery, NGS, and histopathologic testing. 25 It is now imperative that, whenever possible, the aim of any diagnostic biopsy/tissue sampling procedure performed should be to maximize the amount of tissue acquired without compromising patient safety. 26 The quality of the biospecimens depends on the expertise of the surgeons and interventional radiologists in tissue collection. ...

... In another study using alpelisib, the objective response rate (ORR) of recurrent/advanced cervical cancer patients carrying the PIK3CA mutation was 33% [27]. Several cancers show PIK3CA gene mutations and these mutations make them therapeutic targets [26,30,31]. To better understand the potential mechanisms, more research is still needed. ...

... The outcome of the trail was that the combination therapy exhibits better clinical response in patients diagnosed with sarcoma and adrenocortical carcinoma than when temsirolimus was used alone [141]. In another clinical trial, CTRI/2018/05/014178, conducted by Timothy Crook and co-workers in 2020, it was demonstrated that mTOR-based drug combination improved treatment outcomes, like response rate and disease control rate [142]. ...

... Although oral mucositis is a very rare ADR (occurrence rate of less than 10%) arising due to immunotherapy, it was observed in this case. 17,18 This ADR is more commonly seen with the use of anti-PD-1 inhibitors than with the use of CTLA-4 inhibitors. 19 Informed consent was obtained from the patient before the submission of this case report for publication including the use of images. ...